SOURCE: Peak Pharmaceuticals, Inc.

Peak Pharmaceuticals, Inc.

June 30, 2015 09:00 ET

Peak Pharma Updates Market Positioning and Education of CBD Products

Company Streamlines Product Mix and Targets Consumer Awareness of Hemp vs. Pot

DENVER, CO--(Marketwired - Jun 30, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) ("Peak Pharma" or the "Company"), a leading innovator of non-prescription hemp based cannabinoid products, wishes to advise that plans for 2015 summer and fall marketing efforts are underway with a number of initiatives aimed at increasing revenues and growing consumer interest and confidence in its hemp based products.

As part of the Company's overall growth strategy, an internal program is underway which aims to streamline the company's supply chain, including its different manufacturing processes, and to boost channel specific marketing efforts. The recently announced plan to introduce Canna-Pet® Advanced120, a new 120mg product designed for medium to large sized dogs, is another component of the efforts to boost the Company's product offering while delivering an enhanced, second generation Canna-Pet® product that incorporates customer feedback received over the past year.

This consolidation of product lines will reduce manufacturing costs and minimize inventory investment while benefitting from economies of scale by using an outsourced, certified supplement manufacturing facility with a larger production capacity than the current Canna-Pet capability. As part of the new product development, the Company is well underway with package design updates better suited to the growing retail environment.

In related news, the Company is excited by the continued growth in numbers of retailers and veterinarians who now stock our products on their shelves. As a result, management aims to invest in programs designed to reach and assist an even larger number of these very important market influencers within the next few months.

Company CEO Dr. Soren Mogelsvang notes, "Canna-Pet® continues to grow and prosper as we continue to refine and optimize our product portfolio to keep expanding our consumer base. Given that our product lineup is based on hemp, and as such, is virtually devoid of THC, we have been working to determine how this important differentiation from 'marijuana' or 'pot' products would affect market perception and ultimately impact sales. We are delighted to see that a growing segment of consumers take the time to educate themselves and their friends, on the issues, benefits, and features of hemp based CBD and related compounds, and are making their purchasing decisions accordingly. So for us, it's now all about working within this growing community and the regulatory environment to propagate balanced information regarding hemp based products. So we invite our customers to help spread the word and aid us in growing our industry. This is a big part of our social media marketing initiative and it is very exciting to take part in the re-building of the US hemp industry."

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company aims to become a global leader in the hemp supplement industry. For more information visit and follow us on Facebook, Twitter and LinkedIn.

About Canna-Pet® Products for Pet Health
Canna-Pet® offers non-prescription CBD products for domesticated animals such as cats and dogs. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive cannabis products. The company uses non-GMO hemp as starting material and all products are proudly manufactured in the USA. In addition to CBD, Canna-Pet products differ from its competitors through the use of proprietary ratios of hemp derived cannabinoids and terpenes. Canna-Pet® is a trademarked, leading producer of safe, hemp-based, cannabidiol (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). Order online at: or under "Pet Supplies" on Amazon, and join us on Facebook and Twitter.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet® website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.

Contact Information